The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 17, 2017

Filed:

Sep. 27, 2012
Applicant:

Solaeromed Inc., Calgary, CA;

Inventors:

Matthias W. Amrein, Calgary, CA;

Lasantha C. Gunasekara, Calgary, CA;

Ryan Pratt, Mississauga, CA;

Assignee:

SolAero Med Inc., Calgary, CA;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/724 (2006.01); A61K 45/06 (2006.01); A61K 47/48 (2006.01); A61K 35/42 (2015.01); B82Y 5/00 (2011.01); C08B 37/16 (2006.01); C08L 5/16 (2006.01);
U.S. Cl.
CPC ...
A61K 31/724 (2013.01); A61K 35/42 (2013.01); A61K 45/06 (2013.01); A61K 47/48969 (2013.01); B82Y 5/00 (2013.01); C08B 37/0015 (2013.01); C08L 5/16 (2013.01);
Abstract

The invention relates to a method for enhancing a surfactant, in particular a pulmonary surfactant, as well as a method for producing a surfactant enhancement agent, in particular a pulmonary surfactant enhancement agent. The invention also relates to a surfactant enhancement agent and a use of an enhancement agent for enhancing a surfactant, in particular, a pulmonary surfactant. Further, the invention relates to a method of mitigating oxidative damage to pulmonary surfactant by adding a cholesterol-sequestrating agent such as cyclodextrin. Finally, a method is provided for treating a patient having surfactant dysfunction due to oxidative damage to pulmonary surfactant by administering a surfactant-protective amount of a cholesterol-sequestrating agent to protect the surfactant from the negative effects of oxidative degradation. In the examples we show that MβCD, a cholesterol-sequestrating agent, can restore dysfunctional surfactant removed from the lungs of children with cystic fibrosis and non CF bronchiolitis to normal function.


Find Patent Forward Citations

Loading…